Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Identification of novel biomarker as citrullinated inter-alpha-trypsin inhibitor heavy chain 4, specifically increased in sera with experimental and rheumatoid arthritis

Fig. 4

Relationship between citrullinated inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) levels and disease activity in patients with rheumatoid arthritis (RA). ad Correlation between citrullinated ITIH4 levels and disease activity score in 28 joints (DAS28) as measured by C-reactive protein (DAS28-CRP) (a), DAS28-ESR (b), Simplified Disease Activity Index (SDAI) (c), and Clinical Disease Activity Index (CDAI) (d) at baseline in patients with RA (n = 17). e Sera from patients with RA at baseline or 24 weeks after biologic treatment subjected to Western blot analysis using anti-modified citrulline antibodies. Citrullinated ITIH4 levels were decreased after effective treatment. Lanes 1–8: Each individual, lanes 1and 2: abatacept treatment samples, lanes 3–8: infliximab treatment samples, Lanes marked (−): baseline samples; lanes marked (+):posttreatment samples. f and g Correlation between the difference of citrullinated ITIH4 levels (expressed as the normalized difference of band intensity) and the difference of (f) DAS28-CRP or (g) DAS28-ESR before and after treatment (n = 17). r is the correlation coefficient

Back to article page